| Name | Title | Contact Details |
|---|
Samsung Biologics is the most qualified worlds leading Contract Development, Manufacturing and Research Organization, committed to quality-driven development, manufacturing of biopharmaceutical products.
SiChuan Sanherb Biotech is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biotech Medical is a Canton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.
Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion`s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney dysfunction. ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach.